Doc's note: One of the easiest ways to profit during times of fear is to avoid the herd... Sell what everyone wants to buy, buy what everyone is selling.

Today, Rob Spivey, director of research at our corporate affiliate Altimetry, talks about the latest "apocalypse" happening in tech, how investors are overreacting, and why it signals a good time for you to buy...

One software update shouldn't be enough to spook the market...

But investors don't seem to have gotten the message.

In mid-January, an AI business known as Anthropic released a new version of its flagship AI model.

The model, called Claude, is a chatbot similar to ChatGPT. And Claude is now completing work far faster than humans ever could.

Anthropic's update included specific tools built for programmers. Claude doesn't just help write a single line of code anymore. Now it can take a prompt... write a full program... and launch it within hours.

And the market didn't like that one bit.

For years, investors assumed AI would help software companies by boosting developer productivity and lowering costs. They weren't wrong.

But there has always been a second side to that story...

If AI can create software quickly... it can also lower the value of existing software by introducing new competition...

When investors saw this in action, they panicked. And they haven't calmed down yet. The S&P North American Expanded Technology Software Index is down 24% this year.

Companies in niche markets were hit the hardest. Take LegalZoom (LZ)... which, as you might have guessed, sells legal software.

Anthropic's latest Claude release can quickly handle legal tasks like document review. LegalZoom's stock plunged on the news and hasn't recovered. It's down more than 35% since the start of January.

The selling didn't stop there, though. It spread across the market – from niche software providers to industry giants. Customer-relationship management leader Salesforce (CRM) is down almost 30% since the start of 2026.

Most of these businesses sell recurring software subscriptions... a business model known as Software as a Service ("SaaS"). If AI can build in hours what once took engineers weeks to build, pricing power and customer retention could crumble.

That's why this sell-off has been dubbed the "SaaSpocalypse."

We're not saying investors are wrong to be worried...

But the market's reaction has been emotional. That's never a good approach.

On an as-reported basis, the software index now trades around a 20 times price-to-earnings (P/E) ratio. Put simply, software stocks are the cheapest they've been since the index was created in 2018.

Take a look...

Uniform Accounting shows a similar setup. Last year, software companies traded at a 24 times Uniform P/E ratio... right around the market average.

Now, they trade at just 18 times.

Of course, not every software company will escape the AI revolution unscathed. New tech will disrupt certain niches. Some products will be replaced.

But the bullish case for AI investment hasn't changed.

If anything, it's getting stronger...

Hyperscalers are spending at record levels. Memory chips are completely sold out for the year.

That's not what you'd see from an industry worried about a short-term shakeout.

And this isn't new information. Private creditors have feared disruption in certain parts of the software sector for months. As early as the middle of last year, some of them stopped lending to software companies.

The public market is finally catching up. And, as usual, it's overreacting. Big, tech-driven bull markets are never a straight ride up. They tend to come with multiple double-digit pullbacks.

Those pullbacks feel scary in the moment. But as long as credit remains healthy, they tend to become buying opportunities.

We don't see credit stress today. Lending is steady. Earnings expectations remain firm. Valuations have fallen as fear has increased. That's the setup long-term investors should want.

These are the dips you should be buying.

Regards,

Rob Spivey

Editor's note: Tomorrow, one of the most sought-after voices in finance – who has operated at the highest levels of tech and Wall Street for 25 years and has even given expert testimony to congressional committees – is going live with an urgent 2026 market warning... along with a one-of-a-kind strategy designed to double your money (or more) within 90 trading days using regular stocks.

Learn more and save your free seat here.

Recent Articles

View Full Archives
Subscribe to Health & Wealth Bulletin for FREE
Get the Health & Wealth Bulletin delivered straight to your inbox.
About Health & Wealth Bulletin

Here at Health & Wealth Bulletin, our manifesto is to provide a guide for living well – at a good price and on your own terms.

We've told folks the secret to life-changing income in retirement, the exit plan that every investor needs, and the key to beating the market. And our team has been on the leading edge of reporting new discoveries like immunotherapy, the dangers of BPA, the truth about cholesterol, and more.

You see, huge corporate interests and corrupt government institutions would rather people didn't know about many of these concepts... The more ignorant the people are, the better for the government and corporate interests. This keeps folks dependent... and the "nanny state" alive. That's why we spend our days uncovering the truth and sharing it with readers.

Health & Wealth Bulletin is your free guidebook to intriguing health and wealth ideas. It's all about living the best life possible.

About the Editor
Dr. David "Doc" Eifrig
Dr. David "Doc" Eifrig
Editor

Dr. David "Doc" Eifrig has one of the most remarkable resumes of anyone we know in the finance industry. After receiving his Bachelor of Arts degree from Carleton College in Minnesota, he went on to earn a Master of Business Administration degree

from Northwestern University's Kellogg School of Management. There, he graduated on the Dean's List with a double major in finance and international business.

Doc then went to work as an elite derivatives trader at the Goldman Sachs investment bank. He spent a decade on Wall Street with several major institutions, including Chase Manhattan Bank and Yamaichi Securities (then known as the "Goldman Sachs of Japan").

That's when Doc's career took an unconventional turn. Sick of the greed and hypocrisy on Wall Street, he quit his Senior Vice President position to become a doctor. He graduated from Columbia University's postbaccalaureate premedical program and eventually earned his Medical Doctor degree with clinical honors from the University of North Carolina at Chapel Hill. While in medical school, he was elected president of his class and admitted to the Order of the Golden Fleece – the highest honor awarded at the university.

Doc also completed a research fellowship in molecular genetics at Duke University and became a board-eligible eye surgeon. Along the way, he has been published in scientific journals and helped start a small biotechnology company, Mirus Bio, which was sold to Roche for $125 million in 2008.

However, frustrated by Big Medicine's many conflicts, Doc began to look for ways to talk directly with individuals. He wanted to use his background to show them how to take control of their health and wealth. In 2008, Doc joined Stansberry Research and launched his publication, Retirement Millionaire. He has gone on to launch Retirement Trader, which uses options to help people construct safe, reliable income streams. Doc's Income Intelligence seeks out income-producing investments to maximize returns. Prosperity Investor helps investors unlock massive potential gains in health care investing. Every Monday through Friday, Doc shares his views on the latest in the financial and health industries – and tips on how to improve your own life – in Health & Wealth Bulletin.

Doc has also authored five books with four-star ratings (or better) on Amazon. In his spare time, he has run three marathons and several triathlons. He owns and produces his own wine (Eifrig Cellars) in northern Sonoma County, California. Doc is also the CEO of MarketWise, Stansberry Research's parent company.

Back to Top